Astellas Continues Regenerative Cell Therapy Funding, Signs With Cytori For Liver Disease
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Sidetracking the human embryonic stem cell debate in the U.S., Astellas entered a strategic relationship with San Diego firm Cytori Therapeutics, a regenerative medicine company that relies mainly on adipose-derived - or fat-derived - stem cells from patients